Phathom Pharmaceuticals Inc Ordinary shares PHAT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
-
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
-
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
-
Phathom Gets Expanded FDA OK of Voquezna in Non-Erosive GERD
-
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 97.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 112
- Website
- https://www.phathompharma.com
Comparables
Valuation
|
Metric
|
PHAT
|
ARQT
|
SYRE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 2.58 |
Price/Book Value | — | 6.39 | 6.43 |
Price/Sales | 97.67 | 7.54 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PHAT
ARQT
SYRE
Financial Strength
|
Metric
|
PHAT
|
ARQT
|
SYRE
|
|---|---|---|---|
Quick Ratio | 6.11 | 7.90 | 19.26 |
Current Ratio | 6.48 | 8.46 | 19.70 |
Interest Coverage | −4.36 | −5.45 | — |
Quick Ratio
PHAT
ARQT
SYRE
Profitability
|
Metric
|
PHAT
|
ARQT
|
SYRE
|
|---|---|---|---|
Return on Assets (Normalized) | −79.99% | −44.22% | −42.01% |
Return on Equity (Normalized) | — | −132.42% | — |
Return on Invested Capital (Normalized) | −503.81% | −42.92% | −298.64% |
Return on Assets
PHAT
ARQT
SYRE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vmlprvvpbc | Cqbs | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fksskbpf | Tpjvjr | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ylcwwnyt | Hxjytz | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Synxbgv | Vzhzxd | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Wndgsqjx | Lnz | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Jndfhdd | Clng | $28.3 Bil | |||
| Moderna Inc
MRNA
| Qqpthjs | Rcjl | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Tjkpxfrm | Rwpg | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qzmjpxzxq | Djqbhqr | $13.3 Bil | |||
| Incyte Corp
INCY
| Rwzdnvsq | Kbhqttz | $13.0 Bil |
United States